Our firm recently performed two valuations on a pharmaceutical company two years apart. The owners were surprised by the surprisingly large jump in value, far larger than performance improvement might have justified. Continue reading “Optimizing Company Valuation via Cost of Capital by Les Nemethy and Sergey Glekov“